Friday - June 05, 2026

Mantle Cell Lymphoma Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Domain | DelveInsight

DelveInsight’s “Mantle Cell Lymphoma Pipeline Insight, 2026” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in the Mantle Cell Lymphoma pipeline landscape. It covers the Mantle Cell Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. … Continue reading

Asthma Pipeline Shows Strong Momentum as 80+ Pharma Companies in the Race | DelveInsight

DelveInsight’s “Asthma Pipeline Insight 2026” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in the Asthma pipeline landscape. It covers the Asthma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Asthma therapeutics … Continue reading

Myasthenia Gravis Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveInsight

DelveInsight’s, “Myasthenia Gravis Pipeline Insight 2026” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Myasthenia Gravis pipeline landscape. It covers the Myasthenia Gravis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading

Hepatocellular Carcinoma Pipeline Expands as 90+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s “Hepatocellular Carcinoma Pipeline Insight 2026 report provides comprehensive insights about 90+ companies and 95+ pipeline drugs in the Hepatocellular Carcinoma pipeline landscape. It covers the Hepatocellular Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading

Metastatic Colorectal Cancer Pipeline Shows Potential with Active Contributions from 150+ Key Companies | DelveInsight

DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight 2026” report provides comprehensive insights about 150+ companies and 180+ pipeline drugs in Metastatic Colorectal Cancer pipeline landscape. It covers the Metastatic Colorectal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It … Continue reading

Exosomes Pipeline Shows Strong Momentum as 100+ Pharma Companies in the Race | DelveInsight

DelveInsight’s “Exosomes Pipeline Insight 2026” report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in the Exosomes pipeline landscape. It covers the Exosomes Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Exosomes Pipeline … Continue reading

Ulcerative Colitis Clinical Trial Pipeline Accelerates as 70+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s “Ulcerative Colitis Pipeline Insight 2026” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in the Ulcerative Colitis Pipeline Landscape. It covers the Ulcerative Colitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading

Type 1 Diabetes Clinical Trial Pipeline Gains Momentum: 85+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s, “Type 1 Diabetes Pipeline Insight, 2026” report provides comprehensive insights about 85+ companies and 100+ pipeline drugs in Type 1 Diabetes pipeline landscape. It covers the Type 1 Diabetes pipeline drug profiles, including clinical and nonclinical stage products. It … Continue reading

Aicardi Goutières Syndrome Market is Expected to Witness Significant Growth by 2036 Driven by Emerging Targeted Therapies and Rising Disease Awareness | DelveInsight

The market dynamics for Aicardi Goutières Syndrome (AGS) are evolving steadily due to increasing awareness of rare genetic interferonopathies, improvements in genetic diagnostic capabilities, and growing research activities focused on targeted immunomodulatory therapies. Additionally, the development of emerging therapies such … Continue reading